---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001873"
form_type: "8-K"
ticker: "COLL"
cik: "0001267565"
company_name: "COLLEGIUM PHARMACEUTICAL, INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:19:08.672982+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Collegium provides 2025 guidance: product revenue $735M-$750M, adj EBITDA $435M-$450M

## Summary
- Product revenues, net expected $735M-$750M for 2025.
- Jornay PM net revenue expected >$135M in 2025.
- Adjusted EBITDA (excl. SBC) expected $435M-$450M.
- Adjusted operating expenses (excl. SBC) expected $220M-$230M.
- Repurchased $60M in shares in 2024 under $150M buyback program.

## SEC filing metadata
- accession: 0001104659-25-001873
- form_type: 8-K
- ticker: COLL
- cik: 0001267565
- company_name: COLLEGIUM PHARMACEUTICAL, INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/0001104659-25-001873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267565/000110465925001873/tm252196d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001873
- JSON: https://secwatch.observer/filing/0001104659-25-001873.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.